This is a repeat-dose, single-arm, open-label study that will evaluate the potential impact
of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in
adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for
subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to
4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or
Anthracycline and Cyclophosphamide [AC] combination regimen).